All Episodes

August 19, 2021 16 min

Bell2Bell’s latest podcast features Kelsey Ramsden, Co-Founder and CEO of Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF). During the briefing, Ramsden discussed the company’s business model and the evolving regulatory and social environments surrounding psychedelic-assisted therapy.

“We’re a life sciences company that has two primary focal points. One side is digital therapeutics focused on psychedelic therapy, and the other is drug development, again, focused on psychedelic molecules,” Ramsden said. “When we developed our model and our strategy of go-to-market… what we looked at was regulation and the timing of regulatory change to ensure that we were developing horizons of revenue that were going to line up with changes at the government level unlocking some of these molecules. What that meant for us was investigating molecular research that would be the blue-sky horizon, so, independent of when the typical generic MDMA or Psilocybin get approved, we’re in charge of the approval process, meaning we do the clinical research on the novel molecule to get it to market. That is drug development. So, that’s one side.”

Share
Mark as Played

Advertise With Us

Popular Podcasts

CASEWATCH The Gabby Petito Case
Crime Junkie

Crime Junkie

If you can never get enough true crime... Congratulations, you’ve found your people.

Dateline NBC

Dateline NBC

Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations.

For You

    Music, radio and podcasts, all free. Listen online or download the iHeart App.

    Connect

    © 2021 iHeartMedia, Inc.

    • Help
    • Privacy Policy
    • Terms of Use
    • AdChoicesAd Choices